Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 3:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 611 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Oral glucose Clear all

Conditions: Type 2 Diabetes Mellitus
Interventions: Alogliptin, Metformin, Glipizide; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 2,639 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 94
States / cities: Montgomery, Alabama • Muscle Shoals, Alabama • Pell City, Alabama + 91 more

Conditions: Cardiovascular Risk Factor
Interventions: xylitol, 30g, erythritol, 30g, xylitol, 5g, glucose, 30g; Dietary Supplement
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: IGT - Impaired Glucose Tolerance, T2D
Interventions: Oral Glucose Tolerance Test, Hyperglycemic Clamp, Isoglycemic Intravenous Glucose Test, Hyperinsulinemic Euglycemic Clamp and 2H20; Diagnostic Test
Lead sponsor: Yale University; Other
Eligibility: 12 Years to 18 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Type 2 Diabetes
Interventions: vitamin D3, cholecalciferol, Inactive comparator; Dietary Supplement
Lead sponsor: Augusta University; Other
Eligibility: 19 Years to 60 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Diabetes Mellitus, Type 2
Interventions: Quercetin, Acarbose, placebo; Dietary Supplement · Drug
Lead sponsor: Bastyr University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Weight Management, Treatment Of Obesity
Interventions: CE-326,597 100 mg QD, CE-326,597 50 mg QD, CE-326,597 25 mg QD, Placebo, CE-326,597 5mg QD; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 30
States / cities: Phoenix, Arizona • Fresno, California • National City, California + 23 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin detemir; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 66
States / cities: Goodyear, Arizona • Scottsdale, Arizona • Searcy, Arkansas + 55 more

Conditions: Blood Glucose Concentration, Blood Glucose Self Monitoring
Interventions: Water Intake; Behavioral
Lead sponsor: California Polytechnic State University-San Luis Obispo; Other
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: San Luis Obispo, California

Conditions: Healthy Volunteers
Interventions: Placebo, Canagliflozin; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Heart Failure
Interventions: Empagliflozin 10 mg Tab, Placebo Oral Tablet; Drug
Lead sponsor: Saint Luke's Health System; Other
Eligibility: 19 Years to 119 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 10
States / cities: Los Angeles, California • Jacksonville, Florida • Evanston, Illinois + 7 more

Conditions: Diabetes Mellitus, Type 2, Cystic Fibrosis
Interventions: Oral Glucose Tolerance Test, High Glycemic Index Meal, Low Glycemic Index Meal, Test Soda, Fruit juice; Other
Lead sponsor: Emory University; Other
Eligibility: 1 Year and older
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Transgender Women, HIV/AIDS, Cardiovascular Diseases, Metabolic Disease, Coagulopathy
Interventions: Abdominal MR Imaging, Cardiac MRI/MRS, Oral Glucose Tolerance Testing, Whole Body, Lumbar Spine, and Hip DEXA Imaging; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 16 Years to 99 Years · Male only
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus, Type 2
Interventions: LY2963016, Lantus, OAMs; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 759 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 28
States / cities: Montgomery, Alabama • Brooksville, Florida • Fort Lauderdale, Florida + 25 more

Conditions: Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Non Alcoholic Steatohepatitis, NAFLD, NASH
Interventions: Hyperpolarized (HP) 13C, Hyperpolarized 13C-Urea, Magnetic Resonance Imaging, Saline Flush; Drug · Procedure
Lead sponsor: Michael Ohliger, MD PhD; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Chronic Kidney Disease
Interventions: Paricalcitol, Placebo; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Gestational Diabetes, Pregnancy Related
Interventions: Observational; Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 2,179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 9
States / cities: New Haven, Connecticut • Honolulu, Hawaii • Chicago, Illinois + 5 more

Conditions: Preterm Birth Complication, Preterm Birth, Preterm Birth Recurrence, Preeclampsia, Preeclampsia (PE), Hypertensive Disorders of Pregnancy, Support Program, Stress, Resilience, Psychological, Empowerment, Patient, Emotional Stress, Pregnancy, Pregnancy Complications, Pregnancy Induced Hypertension, Neonates and Preterm Infants, Cervical Insufficiency, Social Determinants of Health (SDOH), Cervical Shortening, Disparities in Pregnancy Complications, Disparities, Prenatal Care, Care Coordination
Interventions: Care coordination, Electronic massage, support gift #1, Support gift #2, Support gift #3, Support gift #4, Additional PTBCARE+ support, Stress reduction toolkit - Visit 1 (V1), PTBCARE+ mobile application (app) and website, Sleep, meditation, and Wellness app, Emergency low blood sugar kit, Low dose aspirin (LDA), Visit #2 Stress Reduction Toolkit; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Diabetes
Interventions: Phentermine/Topiramate, Placebo; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 9
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more

Conditions: Prediabetes
Interventions: Sitting OGTT, Standing OGTT, Sitting CGM, Standing CGM; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Coronary Artery Disease
Interventions: Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart); Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 4
States / cities: Atlanta, Georgia

Conditions: Renal Impairment
Interventions: LIK066; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Hypoglycemia Unawareness
Interventions: Carvedilol 3.125 mg, Carvedilol 2.5 mg, Placebo capsule; Drug
Lead sponsor: Owen Chan, PhD; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Diabetes Mellitus, Type 1, Autoimmune Diseases, Diabetes Mellitus, Endocrine System Diseases, Glucose Metabolism Disorders, Immune System Diseases, Metabolic Diseases
Interventions: Glutamine vs. Placebo, Exercise; Drug · Behavioral
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 13 Years to 19 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Diabetes Mellitus
Interventions: NPH, Correction Factor; Drug
Lead sponsor: Hennepin Healthcare Research Institute; Other
Eligibility: 18 Years to 79 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Search by objective public record fields.

Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus

Consumption of Oral Artificial Sweeteners on Platelet Aggregation and Polyol Excretion

Pathogenesis of Youth Onset Type 2 Diabetes and Prediabetes

The Effect of Vitamin D Supplementation on Glucose Metabolism in Non-Diabetic African American Adults

Effects of Quercetin on Blood Sugar and Blood Vessel Function in Type 2 Diabetes.

A Trial In Diabetic Patients To Assess Effect Of CE-326,597 On Glucose Control And Body Weight

Effect of Two Different Fasting Blood Glucose Targets on Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily

Effect of Low Water Intake on Glucose Regulation Measured Using Continuous Glucose Monitoring

Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor on Bone Metabolism in Healthy Volunteers

Empagliflozin Impact on Hemodynamics in Patients With Heart Failure

Redox Imbalance and the Development of Cystic Fibrosis Diabetes

Effects of Gender-Affirming Hormone Therapy Among Transgender Women

A Study in Adults With Type 2 Diabetes

Hyperpolarized Pyruvate (13C) Magnetic Resonance Imaging In Patients With Fatty Liver Disease

Metabolic Effects of Paricalcitol

Glycemic Observation and Metabolic Outcomes in Mothers and Offspring

Personalized Care for Prenatal Stress Reduction & Prevention of Preterm Birth (PTB) Disparities

A VI-0521 Study to Evaluate the Long-term Safety and Efficacy in Type 2 Diabetic Adults

Effects of Standing on Glycemia in Prediabetic Adults

Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery

Study of PK/PD, Safety and Tolerability of LIK066 in Patients With Decreased Renal Function.

Carvedilol in Treating Hypoglycemia Unawareness

Exercise Snacks and Glutamine to Improve Glucose Control in Adolescents With Type 1 Diabetes

Inpatient Diabetes on Corticosteroids